RAMM Pharma Corp.

CNSX:RAMM Stock Report

Market Cap: CA$1.2m

RAMM Pharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Jack Burnett

Chief executive officer

CA$426.6k

Total compensation

CEO salary percentage100.0%
CEO tenure5.2yrs
CEO ownership18.1%
Management average tenureno data
Board average tenure5.2yrs

Recent management updates

Recent updates

How Much Are RAMM Pharma Corp. (CSE:RAMM) Insiders Taking Off The Table?

Dec 18
How Much Are RAMM Pharma Corp. (CSE:RAMM) Insiders Taking Off The Table?

CEO Compensation Analysis

How has Jack Burnett's remuneration changed compared to RAMM Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Jul 31 2024n/an/a

-CA$9m

Apr 30 2024n/an/a

-CA$9m

Jan 31 2024n/an/a

-CA$8m

Oct 31 2023CA$427kCA$427k

-CA$8m

Jul 31 2023n/an/a

-CA$20m

Apr 30 2023n/an/a

-CA$20m

Jan 31 2023n/an/a

-CA$21m

Oct 31 2022CA$675kCA$418k

-CA$21m

Jul 31 2022n/an/a

-CA$7m

Apr 30 2022n/an/a

-CA$9m

Jan 31 2022n/an/a

-CA$8m

Oct 31 2021CA$467kCA$467k

-CA$7m

Jul 31 2021n/an/a

-CA$7m

Apr 30 2021n/an/a

-CA$6m

Jan 31 2021n/an/a

-CA$7m

Oct 31 2020CA$390kCA$390k

-CA$7m

Compensation vs Market: Jack's total compensation ($USD296.84K) is above average for companies of similar size in the Canadian market ($USD164.07K).

Compensation vs Earnings: Jack's compensation has been consistent with company performance over the past year.

CEO

Jack Burnett

5.2yrs

Tenure

CA$426,569

Compensation

Mr. Jackie Peter Burnett also known as Jack, serves as President, Chief Executive Officer and Chairman at Ramm Pharma Holdings Corp. (Formerly known as Ramm Pharma Corp.) and serves as its Director since O...

Board Members

NamePositionTenureCompensationOwnership
Jackie Burnett
President5.2yrsCA$426.57k18.14%
CA$ 216.5k
Daniel Augereau
Independent Director5.2yrsCA$20.00k9.05%
CA$ 108.0k
Eric Klein
Independent Director5.2yrsCA$20.00kno data

5.2yrs

Average Tenure

Experienced Board: RAMM's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 10:48
End of Day Share Price 2024/12/19 00:00
Earnings2024/07/31
Annual Earnings2023/10/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

RAMM Pharma Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution